AMENDED COMMON STOCK PURCHASE WARRANT IMMUNITYBIO, INC.ImmunityBio, Inc. • November 9th, 2023 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. (New York City time) on July 24, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ImmunityBio, Inc., a Delaware corporation (the “Company”), up to ________________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LEASE TERMINATION AGREEMENTLease Termination Agreement • November 9th, 2023 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • California
This Lease Termination Agreement (this “Agreement”) is made as of August 31, 2023 (the “Effective Date”), by and between IMMUNITYBIO, INC., a Delaware corporation (the “Tenant”), and 23 Alaska, LLC, a California limited liability company (the “Landlord”), with reference to the following facts:
ContractImmunityBio, Inc. • November 9th, 2023 • Biological products, (no disgnostic substances) • California
THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 9th, 2023 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (this “Agreement”) is made as of September 11, 2023 (the “Effective Date”) by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), NantCell, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“NantCell”), Nant Capital, LLC (“Nant Capital”), NantMobile, LLC (“NantMobile”) and NantCancerStemCell, LLC (“NCSC” and together with Nant Capital and NantMobile, each a “Purchaser” and collectively the “Purchasers,” and the Purchasers together with the Company and NantCell, each a “Party” and collectively the “Parties”).
